Development and progress of cancer nutrition therapy

doi:10.3969/j.issn.1006-7795.2021.03.028

Abstract

Abstract: Malignant tumor is the main health problem/concern and the one of the leading causes of death in human being, and it seriously threatens people's physical and mental health, economic development, social stability, and national security. Malnutrition is the most common complication in the patients with cancer and an independent risk factor for death in the patient with cancer, leading to not only adverse clinical outcomes (shortened survival time and reduced quality of life), but also a significant socio-economic burden. Therefore, treating malnutrition in the cancer patients is of great significance. Compared with daily diet, food for special medical purpose has some special advantages. Numerous studies have proved that oral nutritional supplement is the most convenient and cheapest nutritional treatment methods, which can promote disease rehabilitation, shorten the length of hospital stay and save medical costs. It is necessary to deepen the understanding of the importance of cancer nutrition, advance the practice of the first-line treatment in clinical work, and develop China's food for special medical purpose, especially cancer special medical food, which will greatly improve the overall level of cancer treatment in China and significantly save medical costs.

Key words: malignant tumor, nutritional therapy, food for special medical purpose

CLC Number:

R459.3

Yu Kaiying, Wang Xiaolin, Shi Hanping. Development and progress of cancer nutrition therapy[J]. Journal of Capital Medical University, 2021, 42(3): 499-502.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2021.03.028

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2021/V42/I3/499

References

[1] International Agency for Research on Cancer (IARC).Latest global cancer data:cancer burden rises to 19.3 million new cases and 10.0 million cancer deaths in 2020[EB/OL].(2020-1-16)[2021-2-22].http://www.iarc.who.int/faq/latest-global-cancer-data-2020-qa/.
[2] 宋春花, 王昆华, 郭增清, 等.中国常见恶性肿瘤患者营养状况调查[J].中国科学:生命科学,2020,50(12):1437-1452.
[3] Warburg O.The chemical constitution of respiration ferment[J].Science,1928,68(1767):437-443.
[4] Tajan M, Vousden K H.Dietary approaches to cancer therapy[J].Cancer Cell, 2020,37(6):767-785.
[5] Weber D D, Aminzadeh-Gohari S, Tulipan J, et al.Ketogenic diet in the treatment of cancer-Where do we stand?[J].Mol Metab, 2020,33:102-121.
[6] Bose S, Allen A E, Locasale J W.The molecular link from diet to cancer cell metabolism[J].Mol Cell,2020,78(6):1034-1044.
[7] Downer S, Berkowitz S A, Harlan T S, et al.Food is medicine:actions to integrate food and nutrition into healthcare[J].BMJ, 2020,369:2482.
[8] Kanarek N, Petrova B, Sabatini D M.Dietary modifications for enhanced cancer therapy[J].Nature,2020,579(7800):507-517.
[9] Rock C L, Thomson C, Gansler T,et al.American Cancer Society guideline for diet and physical activity for cancer prevention[J].CA Cancer J Clin, 2020,70(4):245-271.
[10] 黎介寿.肿瘤营养学的兴起及临床应用[J].肠外与肠内营养,2004,11(1):1-2.
[11] 石汉平, 凌文华,李薇.肿瘤营养学[M].北京:人民卫生出版社, 2012.
[12] 石汉平.肿瘤营养疗法[J].中国肿瘤临床, 2014,41(18):1141-1145.
[13] 石汉平.肿瘤新疗法——代谢调节治疗[J/CD].肿瘤代谢与营养电子杂志,2014,1(1):3-5.
[14] 石汉平.整体营养疗法[J/CD].肿瘤代谢与营养电子杂志,2017,4(2):130-135.
[15] 石汉平.肿瘤是一种代谢性疾病[J/CD].肿瘤代谢与营养电子杂志,2018,5(2):111-116.
[16] 于恺英, 刘俐惠, 石汉平.营养状况是基本生命体征[J/CD].肿瘤代谢与营养电子杂志,2019,6(4):391-395.
[17] 石汉平.营养治疗是肿瘤的一线治疗[J].临床药物治疗杂志,2019,17(4):20-25.
[18] 石汉平.重视肿瘤营养学的学科发展[J].中国医学前沿杂志:电子版, 2016,8(1):1-3.
[19] 石汉平,赵青川,王昆华,等.营养不良的三级诊断[J/CD].肿瘤代谢与营养电子杂志,2015,2(2):31-36.
[20] 石汉平,许红霞,李苏宜,等.营养不良的五阶梯治疗[J/CD].肿瘤代谢与营养电子杂志,2015,2(1):29-33.
[21] 石汉平.营养治疗的疗效评价[J/CD].肿瘤代谢与营养电子杂志,2017,4(4):364-370.
[22] 石汉平,李增宁,王昆华,等.中国抗癌协会肿瘤营养与支持治疗专业委员会.营养管理新模式—HCH[J/CD].肿瘤代谢与营养电子杂志,2015,2(3):23-26.
[23] 石汉平,杨剑,张艳.肿瘤患者营养教育[J/CD].肿瘤代谢与营养电子杂志,2017,4(1):1-6.
[24] Schuetz P, Fehr R, Baechli V, et al.Individualised nutritional support in medical inpatients at nutritional risk:a randomised clinical trial[J].Lancet, 2019,393(10188):2312-2321.
[25] Pedrazzoli P, Caccialanza R, Cotogni P, et al.The advantages of clinical nutrition use in oncologic patients in Italy:real world insights[J].Healthcare (Basel), 2020,8(2):125.
[26] Guan H, Chen S, Huang Q.Effects of enteral immunonutrition in patients undergoing pancreaticoduodenectomy:a Meta-analysis of randomized controlled trials[J].Ann Nutr Metab,2019,74(1):53-61.
[27] Lu Z, Fang Y, Liu C,et al.Early interdisciplinary supportive care in patients with previously untreated metastatic esophagogastric cancer:a phase III randomized controlled trial[J].J Clin Oncol,2021,39(7):748-756.
[28] Tyler R, Barrocas A, Guenter P, et al.ASPEN value project scientific advisory council.Value of nutrition support therapy:impact on clinical and economic outcomes in the united states[J].JPEN J Parenter Enteral Nutr, 2020,44(3):395-406.
[29] Philipson T J, Snider J T, Lakdawalla D N,et al.Impact of oral nutritional supplementation on hospital outcomes[J].Am J Manag Care, 2013,19(2):121-128.
[30] 中国抗癌协会.中国肿瘤营养治疗指南(2020)[M].北京:人民卫生出版社,2020.
[31] 中国抗癌协会肿瘤营养专业委员会.恶性肿瘤营养不良的特征[J/CD].肿瘤代谢与营养电子杂志, 2020, 7(3):276-282.
[32] De van der Schueren M A E, Laviano A, Blanchard H,et al.Systematic review and meta-analysis of the evidence for oral nutritional intervention on nutritional and clinical outcomes during chemo(radio)therapy:current evidence and guidance for design of future trials[J].Ann Oncol, 2018,29(5):1141-1153.
[33] Klek S, Scislo L, Walewska E,et al.Enriched enteral nutrition may improve short-term survival in stage IV gastric cancer patients:a randomized, controlled trial[J].Nutrition, 2017,36:46-53.
[34] Wu J, Li G, Li L,et al.Asparagine enhances LCK signalling to potentiate CD8+ T-cell activation and anti-tumour responses[J].Nat Cell Biol, 2021,23(1):75-86.
[35] Caccialanza R, Goldwasser F, Marschal O, et al.Unmet needs in clinical nutrition in oncology:a multinational analysis of real-world evidence[J].Ther Adv Med Oncol, 2020,12:1758835919899852.